Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
No new kidney treatment findings arrived today, just background reading on how studies work
-
Nothing came in today that changes care or reports new results for people with kidney disease.
-
Most of today's material was a teaching discussion about how kidney trials are designed, not findings from a trial itself.
-
The rest was routine society and journal announcements with no graded evidence behind them.
Today was a quiet day for kidney research. The sweep mainly found educational commentary from a nephrology journal club explaining how clinical trials are built and judged, which is useful background but not new evidence. There were no graded results and nothing that affects treatment or daily decisions for someone living with stage 3 kidney disease. We would rather tell you it was a slow day than dress up weak material as news.
FIND CKD: The Visual Abstract — NephJC
A large phase 3 trial called FIND-CKD tested finerenone, a pill that blocks a hormone that scars the kidneys, in people who have kidney disease but not diabetes. It was the first trial to show that finerenone protects the kidneys in this group. This item is a conference visual summary, so the exact numbers are not shown here, and the next question is how best to combine it with existing treatments.
The Impact of Renin-Angiotensin Aldosterone System Inhibitors in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
This paper combined the results of several randomized trials of RAAS inhibitors, a type of blood pressure drug, in people with IgA nephropathy. IgA nephropathy is a kidney disease where the filters get inflamed. Pooling many trials this way is the strongest kind of evidence. It measured how these drugs affected the kidneys across the trials.
NephJC Short: 24-Month Iptacopan eGFR Data in IgA Nephropathy — NephJC
This is a journal club covering 24-month results for iptacopan, a drug for IgA nephropathy, a common kidney disease. It comes from APPLAUSE-IgAN, a large late-stage randomized trial, and shows the drug helped protect the kidney filtering rate (eGFR) over two years. This is a blog summary, but the underlying trial is strong evidence. Longer-term data like this suggests a real benefit for slowing kidney decline.
Comparison of Dialysate Calcium Concentrations and Arterial Stiffness in Dialysis Patients: A Network Meta-analysis
This pooled several studies of dialysis patients to compare different calcium levels in the dialysis fluid. It looked at how stiff the arteries became, which is a sign of heart risk. Pooling many studies makes the finding stronger. It suggests the calcium level used during dialysis may affect artery stiffness.
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
A large Phase 3 trial tested a drug called atacicept for IgA nephropathy, a common cause of kidney damage. The drug aims to calm the immune signals that drive the disease. The results were published in a major medical journal. A trial this large and carefully run carries real weight for how this disease may be treated.
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC
A phase 3 trial in China called TELIGAN tested telitacicept, a drug that calms the immune system, in adults with IgA nephropathy, a kidney disease driven by the immune system. This early look, at about 9 months (39 weeks), found less protein in the urine, which is a sign of less kidney damage. Protein in the urine is a stand-in marker, not a final outcome, so longer follow-up is needed to know if it truly protects kidney function.
Is TRPC6 inhibition for FSGS a trick or a treat? — NephJC
This was an early (phase 2) trial of a new drug, BI 764198, for FSGS, a disease that scars the tiny filters in the kidney and leaks protein into the urine. People were randomly given either the drug or a dummy pill (placebo), and the results were published in a major journal (the Lancet). An early trial like this tests whether a drug is safe and shows promise. It is a first step, not proof that the drug protects kidneys over the long run.
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC
This trial compared two treatments for primary membranous nephropathy, a disease where the kidney's filter is damaged and leaks protein into the urine. People were randomly assigned to get either obinutuzumab, an antibody given by drip, or tacrolimus, a pill that calms the immune system. It was a head-to-head test to see which better controls the disease, published in a top journal (NEJM). Because it is a mid-size trial, it shows which drug worked better here but does not settle long-term kidney survival.
Finerenone across the proteinuric CKD spectrum — NephJC
This is a journal club discussing finerenone, a drug that lowers protein in the urine and helps protect the kidneys. Two 2026 papers extended the evidence beyond diabetes, including a preplanned subgroup from a large trial called FIND-CKD focused on people with glomerular disease, a type of kidney damage. The exact number of people in that subgroup was not given here. Because it is a subgroup rather than the main trial result, treat it as promising but not final proof.
Long-term mortality and risk of chronic kidney disease in children following severe malaria complicated by acute kidney injury: a prospective observational study.
Researchers followed children who survived severe malaria that had harmed their kidneys. Over the long term, these children had a higher risk of death and of developing lasting kidney disease. This is an observational study, so it shows a strong link but cannot prove malaria alone caused the later kidney problems.
Impact of Anemia and Comorbidity Burden on Disease Progression and Outcomes in Chronic Kidney Disease.
This study looked at how a low blood count (anemia) and other illnesses affect people as their kidney disease worsens. People carrying more of these problems tended to decline faster and have worse outcomes. This shows a link, not proof that treating anemia alone would change the course.
Diagnostic Value of Left Atrioventricular Coupling Index and Left Atrial Stiffness Index for Left Ventricular Diastolic Dysfunction in Patients with Chronic Kidney Disease: A Comparative Study Based on the 2025 ASE Guidelines.
This study tested two ultrasound measures of how well the heart relaxes in people with kidney disease. It checked how well these measures spot early heart stiffness, a common problem in kidney patients. It shows the tools can flag a link to heart trouble, not that using them changes how patients do.
Urinary heavy metal and trace element mixtures in chronic kidney disease: associations and implications for potential reverse causality.
Researchers measured heavy metals and trace elements in the urine of people with kidney disease and looked for patterns. They found links between certain metal mixtures and kidney disease, but a link is not proof of cause. Failing kidneys may change how the body handles these metals, so the direction of the effect is unclear.
Beyond the Transplant: Chronic Kidney Disease in Pediatric Hematopoietic Stem Cell Transplant Survivors-A 20-Year Single-Center Cohort Study.
Doctors followed children who had a stem cell transplant, over 20 years, to see how many later got long-term kidney disease. This kind of study can show a link between the transplant and later kidney trouble, but it cannot prove the transplant was the cause. It is a reminder that these survivors need their kidneys watched for years.
Global Burden of Key Components of Cardiovascular-Kidney-Metabolic Syndrome Among Women of Reproductive Age, 1990-2021.
This report estimated the global burden of cardiovascular-kidney-metabolic syndrome in women of childbearing age from 1990 to 2021. That syndrome links heart, kidney, and metabolic problems together. It maps how common these conditions are, but it only describes populations and does not prove cause.
10-Year Trends in Heart Failure Among Patients With Dialysis and Nondialysis CKD.
This study tracked heart failure over ten years in people with chronic kidney disease, both on dialysis and not. It shows how common heart failure has become in these patients over time. It describes trends in a group, so it shows a pattern and does not test a treatment.
Asymptomatic kidney changes discovered during occupational health screening: age-dependent trends from a large cohort.
Workplace health screening found early kidney changes in people who had no symptoms. In a large group, these hidden changes became more common with age. It shows that kidney damage can be silent, but as an observational snapshot it shows a pattern, not cause.
Prevalence of type 1 and type 2 diabetes among chronic kidney disease patients and laboratorial differences between diabetics and non-diabetics.
This study counted how many people with chronic kidney disease also have type 1 or type 2 diabetes. It also compared lab test results between those with and without diabetes. It gives a snapshot of a group and shows patterns, not proof of cause.
Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD: Target Trial Emulation Study.
This study compared two bone-building drugs, romosozumab and teriparatide, in people who have both weak bones and chronic kidney disease. It looked back at real patient records to check heart safety, so it shows a link and cannot prove cause. It hints at how the two drugs may differ for kidney patients, but a real trial would be needed to be sure.
Real-world effectiveness and safety of difelikefalin for chronic kidney disease-associated pruritus: a systematic review.
This review gathered real-world reports on difelikefalin, a drug for the severe itch that kidney disease can cause. It looked at how well the drug worked and how safe it was outside of trials. Because it pools everyday-use data rather than randomized trials, it shows a link and not firm proof.